BK CD-ROW

Express Mail No.: EV 809 954 749 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Vanderslice et al.

Confirmation No.:

6132

Serial No.:

10/533,693

Art Unit:

Unknown

Filed:

November 7, 2003

Examiner:

Unknown

For:

Combination Products with Carboxylic Acid Derivatives that Inhibit the binding of Integrins to

their Receptors and Other

Therapeutic Compounds

Attorney Docket No.: 017092-0065-999

(CAM 011104-

999065)

REPLY TO THE RAW SEQUENCE LISTING ERROR REPORT

Mail Stop SEQUENCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.821, Applicant, in connection with the above-identified patent application, submits herewith a substitute Sequence Listing in a paper and a computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and a Verified Statement.

It is respectfully requested to enter substitute Sequence Listing and Remarks provided below.

REMARKS

The Sequence Listing has been amended to correct the deficiencies in the computer readable form (CRF) copy indicated in the Raw Sequence Listing Error Report. In particular, the sequence has been identified as Artificial Sequence and the source has been identified as Chemically Synthesized for SEQ ID NO:1.

I hereby state that the content of the paper and the computer readable form copies of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same and include no new matter. Entry of the substitute sequence listing in the above-referenced application is requested.

Application S.N. 10/533,693 Filed Nov. 7, 2003 Docket No. 017092-0065-999

The Commissioner is authorized to charge all required fees, fees under 37 C.F.R. § 1.17 and all required extension of time fees, or credit any overpayment to Jones Day deposit account no. 50-3013.

Respectfully submitted,

Dale L. Rieger (Reg. No. 43,045)

JONES DAY

September 29, 2006

Date:

222 East 41st Street New York, NY 10017 (212) 326-3939